Evidence map›Paper›PMID 35806455›Full record

ArticleInternational journal of molecular sciences2022

Postischemic Neuroprotection of Aminoethoxydiphenyl Borate Associates Shortening of Peri-Infarct Depolarizations.

Rocío Fernández-Serra, Emma Martínez-Alonso, Alberto Alcázar, Mourad Chioua, José Marco-Contelles, Ricardo Martínez-Murillo, Milagros Ramos, Gustavo V Guinea, Daniel González-Nieto

Open access · goldAbstract read
In one paragraph

Article in International journal of molecular sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.4field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 13 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 6 institutions in 1 country.

Rocío Fernández-SerraCenter for Biomedical Technology, Universidad Politécnica de Madrid, 28223 Madrid, Spain.ORCID 0000-0002-7362-117X
Emma Martínez-AlonsoDepartment of Research, Hospital Universitario Ramón y Cajal, IRYCIS, 28034 Madrid, Spain.
Alberto AlcázarDepartment of Research, Hospital Universitario Ramón y Cajal, IRYCIS, 28034 Madrid, Spain.
Mourad ChiouaLaboratory of Medicinal Chemistry, Institute of General Organic Chemistry (CSIC), 28006 Madrid, Spain.
José Marco-ContellesLaboratory of Medicinal Chemistry, Institute of General Organic Chemistry (CSIC), 28006 Madrid, Spain.
Ricardo Martínez-MurilloDepartment of Translational Neuroscience, Instituto Cajal (CSIC), 28002 Madrid, Spain.
Milagros RamosCenter for Biomedical Technology, Universidad Politécnica de Madrid, 28223 Madrid, Spain.
Gustavo V GuineaCenter for Biomedical Technology, Universidad Politécnica de Madrid, 28223 Madrid, Spain.ORCID 0000-0002-4326-3746
Daniel González-NietoCenter for Biomedical Technology, Universidad Politécnica de Madrid, 28223 Madrid, Spain.ORCID 0000-0003-2972-729X
Biomedical Research Networking Center in Bioengineering, Biomaterials and Nanomedicine · ESInstituto de Química Orgánica General · ESInstituto Ramón y Cajal de Investigación Sanitaria · ESInstituto Cajal · ESInstituto de Investigación Sanitaria del Hospital Clínico San Carlos · ESUniversidad Politécnica de Madrid · ES

Funding

Comunidad de Madrid IND2018/BMD-9804Comunidad de Madrid Neurocentro-B2017/BMD-3760ISCIII and FEDER RD21/0006/0019Ministerio de Ciencia e Innovación PID2020-116403RB-I00 funded by MCIN/AEI/10.13039/501100011033Ministry of Economy, Industry and Competitiveness MAT2016-79832-RMinistry of Economy, Industry and Competitiveness SAF2015-65586-R
6 · The paper itself

Abstract

Brain stroke is a highly prevalent pathology and a main cause of disability among older adults. If not promptly treated with recanalization therapies, primary and secondary mechanisms of injury contribute to an increase in the lesion, enhancing neurological deficits. Targeting excitotoxicity and oxidative stress are very promising approaches, but only a few compounds have reached the clinic with relatively good positive outcomes. The exploration of novel targets might overcome the lack of clinical translation of previous efficient preclinical neuroprotective treatments. In this study, we examined the neuroprotective properties of 2-aminoethoxydiphenyl borate (2-APB), a molecule that interferes with intracellular calcium dynamics by the antagonization of several channels and receptors. In a permanent model of cerebral ischemia, we showed that 2-APB reduces the extent of the damage and preserves the functionality of the cortical territory, as evaluated by somatosensory evoked potentials (SSEPs). While in this permanent ischemia model, the neuroprotective effect exerted by the antioxidant scavenger cholesteronitrone F2 was associated with a reduction in reactive oxygen species (ROS) and better neuronal survival in the penumbra, 2-APB did not modify the inflammatory response or decrease the content of ROS and was mostly associated with a shortening of peri-infarct depolarizations, which translated into better cerebral blood perfusion in the penumbra. Our study highlights the potential of 2-APB to target spreading depolarization events and their associated inverse hemodynamic changes, which mainly contribute to extension of the area of lesion in cerebrovascular pathologies.

Indexed as

Brain IschemiaCortical Spreading DepressionAgedBoratesCerebrovascular CirculationHumansInfarctionNeuroprotectionReactive Oxygen SpeciesBoratesReactive Oxygen Species2-APBcholesteronitrone F2hypoperfusionneuroprotectionoxidative stressperi-infarct depolarizationsspreading depolarizationstroke

Identifiers

PMID35806455
PMCPMC9266990
OpenAlexW4283821517

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.